ACTELION Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACTELION, and when can generic versions of ACTELION drugs launch?
ACTELION has eight approved drugs.
There are fifteen US patents protecting ACTELION drugs.
There are two hundred and forty-seven patent family members on ACTELION drugs in thirty-nine countries and thirty-four supplementary protection certificates in seventeen countries.
Summary for ACTELION
International Patents: | 247 |
US Patents: | 15 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 8 |
PTAB Cases with ACTELION as petitioner: | See PTAB cases with ACTELION as petitioner |
Drugs and US Patents for ACTELION
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | 10,828,298 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-006 | Dec 21, 2015 | RX | Yes | No | 10,828,298 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Actelion | UPTRAVI | selexipag | TABLET;ORAL | 207947-008 | Dec 21, 2015 | AB | RX | Yes | No | 10,828,298 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACTELION
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-001 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
Actelion | ZAVESCA | miglustat | CAPSULE;ORAL | 021348-001 | Jul 31, 2003 | 5,472,969 | ⤷ Try a Trial |
Actelion | TRACLEER | bosentan | TABLET;ORAL | 021290-002 | Nov 20, 2001 | 5,292,740 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Oral Suspension | 32 mg | ➤ Subscribe | 2019-02-08 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2017-10-18 |
International Patents for ACTELION Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 33637 | ⤷ Try a Trial |
South Africa | 201101900 | ⤷ Try a Trial |
Hungary | E036071 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ACTELION Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1345920 | CR 2014 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MACITENTAN OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/13/893 20131227 |
1400518 | 2016/047 | Ireland | ⤷ Try a Trial | PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512 |
0526708 | 0290017-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BOSENTAN ELLER ETT SALT DAERAV; NAT. REGISTZRATION NO/DATE: EU/1/02/220/001 20020515; FIRST REGISTRATION: CH 55841 01 20020228 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.